Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 7/20 | 0.39 |
| ▸ | THRA | P10827 | 6/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9929102 | 0.79 | HSD17B10 (0.50) | MAOAMAOBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL6448529 | 0.77 | THRA (0.56) | MAOAMAOBTHRBTHRASMN1; SMN2 | |
| SCHEMBL24770216 | 0.72 | KDM4E (0.38) | ATMTHRBTHRASMN1; SMN2MEN1 | |
| SCHEMBL1545057 | 0.71 | KLK1 (0.47) | THRBTHRASMN1; SMN2MEN1KMT2A | |
| SCHEMBL2476525 | 0.71 | MAPT (0.39) | MAOAMAOBSMN1; SMN2MEN1LMNA | |
| SCHEMBL30016051 | 0.70 | MAPT (0.39) | ATMSMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL24769386 | 0.70 | MAPT (0.39) | ATMSMN1; SMN2MEN1LMNAKMT2A | |
| SCHEMBL9928778 | 0.70 | HSD11B1 (0.41) | MAOAMAOBTHRBMEN1KMT2A | |
| SCHEMBL221422 | 0.70 | MAOA (0.49) | MAOAMAOBMEN1LMNAKMT2A | |
| SCHEMBL7266985 | 0.69 | KMT2A (0.46) | SMN1; SMN2MEN1LMNAKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088817-B2 | Pyrrole derivative having, as substituents, ureido group, aminocarbonly group and bicyclic group which may have substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088817-B2 | Pyrrole derivative having, as substituents, ureido group, aminocarbonly group and bicyclic group which may have substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088817-B2 | Pyrrole derivative having, as substituents, ureido group, aminocarbonly group and bicyclic group which may have substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110136794-A1 | NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDO GROUP, AMINOCARBONLY GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20110136794-A1 | NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDO GROUP, AMINOCARBONLY GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20110136794-A1 | NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDO GROUP, AMINOCARBONLY GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| EP-2319831-A1 | NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDE GROUP, AMINOCARBONYL GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT | Santen Pharmaceutical Co., Ltd (JP) | 2011-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136794-A1 | NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDO GROUP, AMINOCARBONLY GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT | IL6, IL6ST, UACA | MAOA 2036/4885MAOB 1296/4885ATM 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.